Plecaz MR

Plecaz MR



Pharmaniaga Manufacturing Berhad


Pharmaniaga Logistics
Concise Prescribing Info
Gliclazide modified-release
NIDDM in adults when dietary measures, physical exercise & wt loss alone are insufficient to control blood glucose.
Dosage/Direction for Use
60 mg once daily. Max: 120 mg daily.
Should be taken with food.
Hypersensitivity to gliclazide, other sulphonylureas or sulphonamides. Type 1 diabetes (IDDM); diabetic pre-coma & coma, diabetic ketoacidosis. Concomitant use w/ miconazole. Severe renal & hepatic insufficiency. Lactation.
Special Precautions
Increased risk of hypoglycaemia due to low-calorie diet, prolonged or strenuous exercise, alcohol intake or if used w/ other hypoglycaemics; malnutrition, irregular mealtimes, skipping meals, fasting or dietary changes; imbalance between physical exercise & carbohydrate intake; overdosage; thyroid disorders, hypopituitarism, adrenal insufficiency; severe vascular disease (severe CHD & carotid impairment, diffuse vascular disease), w/drawal of prolonged &/or high-dose corticosteroid therapy. Poor blood glucose control due to fever, trauma, infection or surgical intervention. G6PD deficiency; dysglycaemia; porphyria. Regularly monitor blood glucose levels & glycated Hb levels. Not to be used by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Concomitant use w/ St. John's wort (Hypericum perforatum), fluoroquinolone. May affect ability to drive & use machines. Renal & hepatic insufficiency. Avoid use during pregnancy. Childn & adolescents. Elderly.
Adverse Reactions
Hypoglycaemia; GI disturbances eg, abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, constipation.
Drug Interactions
Increased risk of hypoglycaemia w/ miconazole systemic/oromucosal gel, systemic phenylbutazone, alcohol. Potentiated blood glucose-lowering effect w/ other antidiabetic agents (insulins, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonist), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H2-receptor antagonists, MAOIs, sulphonamides, clarithromycin, NSAIDs. Diabetogenic effect of danazol. Increased blood glucose levels w/ chlorpromazine, glucocorticoids, ritodrine, salbutamol, terbutaline IV. Potentiated anticoagulation w/ warfarin. Decreased exposure by St. John's wort. Risk of dysglycaemia w/ fluoroquinolones.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Plecaz MR tab 60 mg
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in